The Company achieved a record EBITDA of $0.7M (CAD $0.9M) in Q3 2024, marking its third consecutive quarter of positive EBITDA.Quarterly billed revenue was $8.1M (CAD $11.1M) and YTD revenue was $23.9 ...
Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...